Seed-derived Therapeutic Protein for Acute Ischemic Stroke

Information

  • Research Project
  • 9017347
  • ApplicationId
    9017347
  • Core Project Number
    R03NS095246
  • Full Project Number
    1R03NS095246-01
  • Serial Number
    095246
  • FOA Number
    PA-13-304
  • Sub Project Id
  • Project Start Date
    9/30/2015 - 9 years ago
  • Project End Date
    5/31/2016 - 8 years ago
  • Program Officer Name
    BOSETTI, FRANCESCA
  • Budget Start Date
    9/30/2015 - 9 years ago
  • Budget End Date
    5/31/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/23/2015 - 9 years ago

Seed-derived Therapeutic Protein for Acute Ischemic Stroke

Program Director/Principal Investigator (Last, first, middle): Wang, Kevin, Yueju A stroke occurs when a blood clot or a narrowing of blood vessels prevents blood from getting to the brain. Globally, stroke is the second leading cause of death among people over the age of 60 years. It is also a major source of serious, long-term disability. The only clot- busting drug approved for the treatment of acute ischemic stroke (AIS) disease is a recombinant human tissue plasminogen activator (rt-PA) obtained from Chinese Hamster Ovary cell (CHO) lines. However, yields of rt-PA produced in CHO cells are relatively low, while the dose of rt-PA required for treatment is high, making this therapy very expensive for developing countries. Therefore, a more efficient method of providing rt-PA would greatly reduce the cost and beof great benefit to patients suffering from acute ischemic stroke disease. The objective of the proposed project is to develop a low-cost, plant seed-based platform for the large scale production of functional t-PA for treatment of acute ischemic stroke patients. Our preliminary data revealed that overexpression of several blood-clot dissolving serine protease genes in plant leaves resulted in death of the leaf tissue. In contrast, our preliminary data also indicated that a recombinant vampire bat plasminogen activator (DSPA?1) could be reliably produced in seeds with sufficient activity to dissolve human blood clots. In this project, appropriate plant expression vectors will be developed to target t-PA gene expression and production to seeds in order to obtain high levels of expression and increased stability of the end product. Transgenic rt-PA plant lines will be generated and in vitro evaluation of seed- derived rt-PA, such as fibrin degradatin and human clot-dissolving assay, will be performed. The overall goal is to develop a seed-based platform in plants for potential large scale, low- cost production of functional rt-PA for the treatment of AIS in humans. 1 Research Strategy

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R03
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
    23298
  • Indirect Cost Amount
    2299
  • Total Cost
    25597
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    SCHOOLS OF EDUCATION
  • Funding ICs
    NINDS:25597\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MGB
  • Study Section Name
    Molecular Genetics B Study Section
  • Organization Name
    NORTHEASTERN STATE UNIVERSITY
  • Organization Department
    PSYCHOLOGY
  • Organization DUNS
    072400500
  • Organization City
    TAHLEQUAH
  • Organization State
    OK
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    744642301
  • Organization District
    UNITED STATES